Drugs / 2-chlorodeoxyadenosine
2-chlorodeoxyadenosine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01295593 | Dec 2010 → Apr 2013 | B-cell chronic lymphocytic leukemia | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03585686 | Jun 2018 → Apr 2023 | Langerhans cell histiocytosis | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02205762 | Nov 2016 → Jul 2026 overdue | Langerhans cell histiocytosis | North American Consortium for Histiocytosis | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00003746 Comparator | Sep 1998 → Nov 2005 | leukemia | Swiss Cancer Institute | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2'-chlorodeoxyadenosine | “The combination of VPA with fludarabine or 2-Chlorodeoxyadenosine (CdA, Cladribine) results in synergistic loss of B-CLL cell viability, and significant increase in apoptosis.” NCT01295593 ↗5“Here, we combined cytosine-arabinoside (Ara-C) and 2'-chlorodeoxyadenosine (2-CdA) with targeted therapy to achieve stable remission.” PMID 37216396 ↗ Sep 2023 |
| Known as | 2-CdA | “Here, we combined cytosine-arabinoside (Ara-C) and 2'-chlorodeoxyadenosine (2-CdA) with targeted therapy to achieve stable remission.” PMID 37216396 ↗ Sep 2023 |
| Known as | CDA | “The combination of VPA with fludarabine or 2-Chlorodeoxyadenosine (CdA, Cladribine) results in synergistic loss of B-CLL cell viability, and significant increase in apoptosis.” NCT01295593 ↗1“2-chlorodeoxyadenosine (CDA) daily” NCT00003746 ↗ |
| Known as | Cladribine | “The combination of VPA with fludarabine or 2-Chlorodeoxyadenosine (CdA, Cladribine) results in synergistic loss of B-CLL cell viability, and significant increase in apoptosis.” NCT01295593 ↗1“Daily administration of 2-chlorodeoxyadenosine (Cladribine, CDA) is a standard treatment for hairy cell leukemia, but may cause severe neutropenia and neutropenic fever.” PMID 19672771 ↗ Sep 2009 |
| Modality | Small molecule | “CdA, a purine nucleoside analog active in B-CLL.” NCT01295593 ↗ |
| Route | Subcutaneous | “daily subcutaneous bolus injections of cladribine (2-CDA)” NCT00003746 ↗ |